{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T06:20:31Z","timestamp":1785392431221,"version":"3.55.0"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Shanghai Science and Technology Innovation Initiative, Yangfan Program","award":["24YF2735100"],"award-info":[{"award-number":["24YF2735100"]}]},{"name":"Shanghai East Hospital Youth Research Cultivation Funding","award":["DFPY2024009"],"award-info":[{"award-number":["DFPY2024009"]}]},{"name":"Key Disciplines Group Construction Project of Shanghai Pudong New Area Health Commission","award":["PWZxq2022-10"],"award-info":[{"award-number":["PWZxq2022-10"]}]},{"name":"Medical Discipline Construction Project of Pudong Health Committee of Shanghai","award":["PWYgy 2021-07"],"award-info":[{"award-number":["PWYgy 2021-07"]}]},{"name":"Key Discipline Construction Project of Shanghai East Hospital","award":["2024-DFZD-003S"],"award-info":[{"award-number":["2024-DFZD-003S"]}]},{"name":"Clinical Research Project of Shanghai East Hospital","award":["DFLC2022007"],"award-info":[{"award-number":["DFLC2022007"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"DOI":"10.1186\/s12964-025-02408-4","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T13:09:44Z","timestamp":1758805784000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Glioma drug development benefits from emerging phase 0 and window-of-opportunity trial paradigm"],"prefix":"10.1186","volume":"23","author":[{"given":"Shenzhong","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunlong","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"key":"2408_CR1","first-page":"v1","volume":"24","author":"QT Ostrom","year":"2022","unstructured":"Ostrom QT, Price M, Neff C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the united States in 2015\u20132019. Neurooncology. 2022;24:v1\u201395.","journal-title":"Neurooncology"},{"key":"2408_CR2","first-page":"299","volume":"70","author":"AC Tan","year":"2020","unstructured":"Tan AC, Ashley DM, L\u00f3pez GY, Malinzak M, Friedman HS, Khasraw M. Management of glioblastoma: state of the Art and future directions. CA Cancer J Clin. 2020;70:299\u2013312.","journal-title":"CA Cancer J Clin"},{"key":"2408_CR3","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The Blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252\u201364.","journal-title":"Nat Rev Cancer"},{"key":"2408_CR4","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1001\/jamaoncol.2020.1024","volume":"6","author":"DA Reardon","year":"2020","unstructured":"Reardon DA, Brandes AA, Omuro A, et al. Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the checkmate 143 phase 3 randomized clinical trial. JAMA Oncol. 2020;6:1003\u201310.","journal-title":"JAMA Oncol"},{"key":"2408_CR5","first-page":"180","volume":"22","author":"J Wei","year":"2020","unstructured":"Wei J, Chen P, Gupta P, et al. Immune biology of glioma-associated macrophages and microglia: functional and therapeutic implications. Neuro Oncol. 2020;22:180\u201394.","journal-title":"Neuro Oncol"},{"key":"2408_CR6","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.cell.2019.06.024","volume":"178","author":"C Neftel","year":"2019","unstructured":"Neftel C, Laffy J, Filbin MG, et al. An integrative model of cellular states, plasticity, and genetics for glioblastoma. Cell. 2019;178:835\u2013e849821.","journal-title":"Cell"},{"key":"2408_CR7","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1038\/s41593-018-0227-9","volume":"21","author":"A Louveau","year":"2018","unstructured":"Louveau A, Herz J, Alme MN, et al. CNS lymphatic drainage and neuroinflammation are regulated by meningeal lymphatic vasculature. Nat Neurosci. 2018;21:1380\u201391.","journal-title":"Nat Neurosci"},{"key":"2408_CR8","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1038\/s41591-023-02464-8","volume":"29","author":"K Singh","year":"2023","unstructured":"Singh K, Hotchkiss KM, Parney IF, et al. Correcting the drug development paradigm for glioblastoma requires serial tissue sampling. Nat Med. 2023;29:2402\u20135.","journal-title":"Nat Med"},{"key":"2408_CR9","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1093\/neuonc\/noy027","volume":"20","author":"AM Vanderbeek","year":"2018","unstructured":"Vanderbeek AM, Rahman R, Fell G, et al. The clinical trials landscape for glioblastoma: is it adequate to develop new treatments? Neuro Oncol. 2018;20:1034\u201343.","journal-title":"Neuro Oncol"},{"key":"2408_CR10","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1093\/neuonc\/nox144","volume":"20","author":"JJ Mandel","year":"2017","unstructured":"Mandel JJ, Yust-Katz S, Patel AJ, et al. Inability of positive phase II clinical trials of investigational treatments to subsequently predict positive phase III clinical trials in glioblastoma. Neuro Oncol. 2017;20:113\u201322.","journal-title":"Neuro Oncol"},{"key":"2408_CR11","doi-asserted-by":"publisher","first-page":"a020412","DOI":"10.1101\/cshperspect.a020412","volume":"7","author":"R Daneman","year":"2015","unstructured":"Daneman R, Prat A. The blood-brain barrier. Cold Spring Harb Perspect Biol. 2015;7:a020412.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"2408_CR12","doi-asserted-by":"crossref","unstructured":"Chernov AN, Alaverdian DA, Galimova ES, Renieri A, Shamova OV. The phenomenon of multidrug resistance in glioblastomas. Hematology\/ Oncology and Stem Cell Therapy; 2021.","DOI":"10.1016\/j.hemonc.2021.05.006"},{"key":"2408_CR13","doi-asserted-by":"crossref","unstructured":"Steeg PS. The blood\u2013tumour barrier in cancer biology and therapy. Nat Reviews Clin Oncol 2021.","DOI":"10.1038\/s41571-021-00529-6"},{"key":"2408_CR14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1602\/neurorx.2.1.3","volume":"2","author":"WM Pardridge","year":"2005","unstructured":"Pardridge WM. The Blood-Brain barrier: bottleneck in brain drug development. NeuroRx. 2005;2:3\u201314.","journal-title":"NeuroRx"},{"key":"2408_CR15","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s11095-022-03172-7","volume":"39","author":"SG Summerfield","year":"2022","unstructured":"Summerfield SG, Yates JWT, Fairman DA. Free drug Theory \u2013 No longer just a hypothesis?? Pharm Res. 2022;39:213\u201322.","journal-title":"Pharm Res"},{"key":"2408_CR16","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1093\/annonc\/mdt180","volume":"24","author":"S Schmitz","year":"2013","unstructured":"Schmitz S, Hamoir M, Reychler H, et al. Tumour response and safety of cetuximab in a window pre-operative study in patients with squamous cell carcinoma of the head and neck. Ann Oncol. 2013;24:2261\u20136.","journal-title":"Ann Oncol"},{"key":"2408_CR17","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1093\/annonc\/mdq622","volume":"22","author":"B Glimelius","year":"2011","unstructured":"Glimelius B, Lahn M. Window-of-opportunity trials to evaluate clinical activity of new molecular entities in oncology. Ann Oncol. 2011;22:1717\u201325.","journal-title":"Ann Oncol"},{"key":"2408_CR18","doi-asserted-by":"crossref","unstructured":"Farlow JL, Birkeland AC, Swiecicki PL, Brenner JC, Spector ME. Window of opportunity trials in head and neck cancer. J Cancer Metastasis Treat 2019;5.","DOI":"10.20517\/2394-4722.2018.100"},{"key":"2408_CR19","doi-asserted-by":"publisher","first-page":"2932","DOI":"10.1158\/1078-0432.CCR-14-1428","volume":"21","author":"A Leary","year":"2015","unstructured":"Leary A, Evans A, Johnston SRD, et al. Antiproliferative effect of lapatinib in HER2-Positive and HER2-Negative\/HER3-High breast cancer: results of the presurgical randomized MAPLE trial (CRUK E\/06\/039). Clin Cancer Res. 2015;21:2932\u201340.","journal-title":"Clin Cancer Res"},{"key":"2408_CR20","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1016\/S1470-2045(20)30458-7","volume":"21","author":"I Smith","year":"2020","unstructured":"Smith I, Robertson J, Kilburn L, et al. Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial. Lancet Oncol. 2020;21:1443\u201354.","journal-title":"Lancet Oncol"},{"key":"2408_CR21","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1158\/1078-0432.CCR-14-1998","volume":"21","author":"TK Owonikoko","year":"2015","unstructured":"Owonikoko TK, Ramalingam SS, Miller DL, et al. A translational, pharmacodynamic, and Pharmacokinetic phase IB clinical study of everolimus in resectable Non\u2013Small cell lung cancer. Clin Cancer Res. 2015;21:1859\u201368.","journal-title":"Clin Cancer Res"},{"key":"2408_CR22","doi-asserted-by":"publisher","first-page":"4991","DOI":"10.1002\/cam4.3131","volume":"9","author":"L Nogova","year":"2020","unstructured":"Nogova L, Mattonet C, Scheffler M, et al. Sorafenib and everolimus in patients with advanced solid tumors and KRAS-mutated NSCLC: A phase I trial with early pharmacodynamic FDG-PET assessment. Cancer Med. 2020;9:4991\u20135007.","journal-title":"Cancer Med"},{"key":"2408_CR23","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/j.ccell.2023.07.011","volume":"41","author":"SL Topalian","year":"2023","unstructured":"Topalian SL, Forde PM, Emens LA, Yarchoan M, Smith KN, Pardoll DM. Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy. Cancer Cell. 2023;41:1551\u201366.","journal-title":"Cancer Cell"},{"key":"2408_CR24","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/nrclinonc.2016.195","volume":"14","author":"S Liti\u00e8re","year":"2017","unstructured":"Liti\u00e8re S, Collette S, de Vries EG, Seymour L, Bogaerts J. RECIST - learning from the past to build the future. Nat Rev Clin Oncol. 2017;14:187\u201392.","journal-title":"Nat Rev Clin Oncol"},{"key":"2408_CR25","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ejca.2016.03.082","volume":"62","author":"LH Schwartz","year":"2016","unstructured":"Schwartz LH, Seymour L, Liti\u00e8re S, et al. RECIST 1.1 - Standardisation and disease-specific adaptations: perspectives from the RECIST working group. Eur J Cancer. 2016;62:138\u201345.","journal-title":"Eur J Cancer"},{"key":"2408_CR26","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","volume":"62","author":"LH Schwartz","year":"2016","unstructured":"Schwartz LH, Liti\u00e8re S, de Vries E, et al. RECIST 1.1-Update and clarification: from the RECIST committee. Eur J Cancer. 2016;62:132\u20137.","journal-title":"Eur J Cancer"},{"key":"2408_CR27","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"Boellaard R, Delgado-Bolton R, Oyen WJ, et al. FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328\u201354.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2408_CR28","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/nrc2066","volume":"7","author":"S Kummar","year":"2007","unstructured":"Kummar S, Kinders R, Rubinstein L, et al. Compressing drug development timelines in oncology using phase \u20180\u2019 trials. Nat Rev Cancer. 2007;7:131\u20139.","journal-title":"Nat Rev Cancer"},{"key":"2408_CR29","doi-asserted-by":"publisher","first-page":"3675","DOI":"10.1158\/1078-0432.CCR-07-4560","volume":"14","author":"AJ Murgo","year":"2008","unstructured":"Murgo AJ, Kummar S, Rubinstein L, et al. Designing phase 0 cancer clinical trials. Clin Cancer Res. 2008;14:3675\u201382.","journal-title":"Clin Cancer Res"},{"key":"2408_CR30","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41416-019-0621-4","volume":"122","author":"F Aroldi","year":"2020","unstructured":"Aroldi F, Lord SR. Window of opportunity clinical trial designs to study cancer metabolism. Br J Cancer. 2020;122:45\u201351.","journal-title":"Br J Cancer"},{"key":"2408_CR31","doi-asserted-by":"publisher","first-page":"5777","DOI":"10.1158\/1078-0432.CCR-19-0133","volume":"25","author":"AC Tien","year":"2019","unstructured":"Tien AC, Li J, Bao X, et al. A phase 0 trial of ribociclib in recurrent glioblastoma patients incorporating a tumor Pharmacodynamic- and Pharmacokinetic-Guided expansion cohort. Clin Cancer Res. 2019;25:5777\u201386.","journal-title":"Clin Cancer Res"},{"key":"2408_CR32","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.annonc.2020.11.007","volume":"32","author":"MJM Magbanua","year":"2021","unstructured":"Magbanua MJM, Swigart LB, Wu HT, et al. Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival. Ann Oncol. 2021;32:229\u201339.","journal-title":"Ann Oncol"},{"key":"2408_CR33","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/j.ccell.2023.04.008","volume":"41","author":"MJM Magbanua","year":"2023","unstructured":"Magbanua MJM, Brown Swigart L, Ahmed Z, et al. Clinical significance and biology of Circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy. Cancer Cell. 2023;41:1091\u2013e11021094.","journal-title":"Cancer Cell"},{"key":"2408_CR34","doi-asserted-by":"publisher","first-page":"e438","DOI":"10.1016\/S1470-2045(23)00453-9","volume":"24","author":"P Karschnia","year":"2023","unstructured":"Karschnia P, Smits M, Reifenberger G, et al. A framework for standardised tissue sampling and processing during resection of diffuse intracranial glioma: joint recommendations from four RANO groups. Lancet Oncol. 2023;24:e438\u201350.","journal-title":"Lancet Oncol"},{"key":"2408_CR35","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/s41586-020-2209-9","volume":"580","author":"M Touat","year":"2020","unstructured":"Touat M, Li YY, Boynton AN, et al. Mechanisms and therapeutic implications of hypermutation in gliomas. Nature. 2020;580:517\u201323.","journal-title":"Nature"},{"key":"2408_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11060-021-03785-9","volume":"154","author":"S Dhawan","year":"2021","unstructured":"Dhawan S, Venteicher AS, Butler WE, Carter BS, Chen CC. Clinical outcomes as a function of the number of samples taken during stereotactic needle biopsies: a meta-analysis. J Neurooncol. 2021;154:1\u201311.","journal-title":"J Neurooncol"},{"key":"2408_CR37","doi-asserted-by":"publisher","first-page":"1014711","DOI":"10.3389\/fonc.2022.1014711","volume":"12","author":"S Katzendobler","year":"2022","unstructured":"Katzendobler S, Do A, Weller J, et al. The value of stereotactic biopsy of primary and recurrent brain metastases in the era of precision medicine. Front Oncol. 2022;12:1014711.","journal-title":"Front Oncol"},{"key":"2408_CR38","doi-asserted-by":"publisher","first-page":"E967","DOI":"10.1093\/neuros\/nyz218","volume":"85","author":"N Sanai","year":"2019","unstructured":"Sanai N. Phase 0 clinical trial strategies for the neurosurgical oncologist. Neurosurgery. 2019;85:E967\u201374.","journal-title":"Neurosurgery"},{"key":"2408_CR39","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1148\/radiology.166.3.2829270","volume":"166","author":"F Earnest t","year":"1988","unstructured":"Earnest t F, Kelly PJ, Scheithauer BW, et al. Cerebral astrocytomas: histopathologic correlation of MR and CT contrast enhancement with stereotactic biopsy. Radiology. 1988;166:823\u20137.","journal-title":"Radiology"},{"key":"2408_CR40","doi-asserted-by":"publisher","first-page":"865","DOI":"10.3171\/jns.1987.66.6.0865","volume":"66","author":"PJ Kelly","year":"1987","unstructured":"Kelly PJ, Daumas-Duport C, Kispert DB, Kall BA, Scheithauer BW, Illig JJ. Imaging-based stereotaxic serial biopsies in untreated intracranial glial neoplasms. J Neurosurg. 1987;66:865\u201374.","journal-title":"J Neurosurg"},{"key":"2408_CR41","doi-asserted-by":"crossref","unstructured":"Kelly PJ, Daumas-Duport C, Scheithauer BW, Kall BA, Kispert DB. Stereotactic Histologic Correlations of Computed Tomography- and Magnetic Resonance Imaging-Defined Abnormalities in Patients With Glial Neoplasms. Mayo Clinic Proceedings 1987;62:450\u2013459.","DOI":"10.1016\/S0025-6196(12)65470-6"},{"key":"2408_CR42","first-page":"1568","volume":"22","author":"MA Vogelbaum","year":"2020","unstructured":"Vogelbaum MA, Krivosheya D, Borghei-Razavi H, et al. Phase 0 and window of opportunity clinical trial design in neuro-oncology: a RANO review. Neurooncol. 2020;22:1568\u201379.","journal-title":"Neurooncol"},{"key":"2408_CR43","first-page":"vdab053","volume":"3","author":"DMJ M\u00fcller","year":"2021","unstructured":"M\u00fcller DMJ, De Swart ME, Ardon H, et al. Timing of glioblastoma surgery and patient outcomes: a multicenter cohort study. Neurooncol Adv. 2021;3:vdab053.","journal-title":"Neurooncol Adv"},{"key":"2408_CR44","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1093\/neuonc\/noac193","volume":"25","author":"P Karschnia","year":"2023","unstructured":"Karschnia P, Young JS, Dono A, et al. Prognostic validation of a new classification system for extent of resection in glioblastoma: A report of the RANO resect group. Neuro Oncol. 2023;25:940\u201354.","journal-title":"Neuro Oncol"},{"key":"2408_CR45","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41572-024-00516-y","volume":"10","author":"M Weller","year":"2024","unstructured":"Weller M, Wen PY, Chang SM, et al. Glioma. Nat Rev Dis Primers. 2024;10:33.","journal-title":"Nat Rev Dis Primers"},{"key":"2408_CR46","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41587-023-01900-x","volume":"42","author":"A Katti","year":"2024","unstructured":"Katti A, Vega-P\u00e9rez A, Foronda M, et al. Generation of precision preclinical cancer models using regulated in vivo base editing. Nat Biotechnol. 2024;42:437\u201347.","journal-title":"Nat Biotechnol"},{"key":"2408_CR47","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1158\/2159-8290.CD-11-0284","volume":"2","author":"I Vivanco","year":"2012","unstructured":"Vivanco I, Robins HI, Rohle D, et al. Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov. 2012;2:458\u201371.","journal-title":"Cancer Discov"},{"key":"2408_CR48","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.1200\/JCO.2003.21.13.2508","volume":"21","author":"FF Lang","year":"2003","unstructured":"Lang FF, Bruner JM, Fuller GN, et al. Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J Clin Oncol. 2003;21:2508\u201318.","journal-title":"J Clin Oncol"},{"key":"2408_CR49","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1200\/JCO.2017.75.8219","volume":"36","author":"FF Lang","year":"2018","unstructured":"Lang FF, Conrad C, Gomez-Manzano C, et al. Phase I study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma. J Clin Oncol. 2018;36:1419\u201327.","journal-title":"J Clin Oncol"},{"key":"2408_CR50","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s40478-020-01044-y","volume":"8","author":"DF Marker","year":"2020","unstructured":"Marker DF, Pearce TM. Homozygous deletion of CDKN2A by fluorescence in situ hybridization is prognostic in grade 4, but not grade 2 or 3, IDH-mutant Astrocytomas. Acta Neuropathol Commun. 2020;8:169.","journal-title":"Acta Neuropathol Commun"},{"key":"2408_CR51","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1016\/j.cell.2024.03.029","volume":"187","author":"AC Greenwald","year":"2024","unstructured":"Greenwald AC, Darnell NG, Hoefflin R, et al. Integrative Spatial analysis reveals a multi-layered organization of glioblastoma. Cell. 2024;187:2485\u2013e25012426.","journal-title":"Cell"},{"key":"2408_CR52","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.ccell.2024.03.008","volume":"42","author":"A Spitzer","year":"2024","unstructured":"Spitzer A, Gritsch S, Nomura M, et al. Mutant IDH inhibitors induce lineage differentiation in IDH-mutant oligodendroglioma. Cancer Cell. 2024;42:904\u2013e914909.","journal-title":"Cancer Cell"},{"key":"2408_CR53","doi-asserted-by":"publisher","first-page":"3116","DOI":"10.1038\/s41467-018-05036-4","volume":"9","author":"HJ Jun","year":"2018","unstructured":"Jun HJ, Appleman VA, Wu H-J, et al. A PDGFR\u03b1-driven mouse model of glioblastoma reveals a stathmin1-mediated mechanism of sensitivity to vinblastine. Nat Commun. 2018;9:3116.","journal-title":"Nat Commun"},{"key":"2408_CR54","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41591-018-0337-7","volume":"25","author":"TF Cloughesy","year":"2019","unstructured":"Cloughesy TF, Mochizuki AY, Orpilla JR, et al. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med. 2019;25:477\u201386.","journal-title":"Nat Med"},{"key":"2408_CR55","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.1200\/JCO.19.03327","volume":"38","author":"IK Mellinghoff","year":"2020","unstructured":"Mellinghoff IK, Ellingson BM, Touat M, et al. Ivosidenib in isocitrate dehydrogenase 1-Mutated advanced glioma. J Clin Oncol. 2020;38:3398\u2013406.","journal-title":"J Clin Oncol"},{"key":"2408_CR56","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1056\/NEJMoa2304194","volume":"389","author":"IK Mellinghoff","year":"2023","unstructured":"Mellinghoff IK, Bent MJvd, Blumenthal DT, et al. Vorasidenib in IDH1- or IDH2-Mutant Low-Grade glioma. N Engl J Med. 2023;389:589\u2013601.","journal-title":"N Engl J Med"},{"key":"2408_CR57","doi-asserted-by":"publisher","first-page":"3510","DOI":"10.1200\/JCO.21.02166","volume":"40","author":"IK Mellinghoff","year":"2022","unstructured":"Mellinghoff IK, Cloughesy TF. Balancing risk and efficiency in drug development for rare and challenging tumors: A new paradigm for glioma. J Clin Oncol. 2022;40:3510\u20139.","journal-title":"J Clin Oncol"},{"key":"2408_CR58","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13045-022-01364-7","volume":"15","author":"B Zhao","year":"2022","unstructured":"Zhao B, Li H, Xia Y, et al. Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy. J Hematol Oncol. 2022;15:153.","journal-title":"J Hematol Oncol"},{"key":"2408_CR59","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12964-023-01098-0","volume":"21","author":"B Zhao","year":"2023","unstructured":"Zhao B, Wu J, Li H, et al. Recent advances and future challenges of tumor vaccination therapy for recurrent glioblastoma. Cell Commun Signal. 2023;21:74.","journal-title":"Cell Commun Signal"},{"key":"2408_CR60","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41586-023-06623-2","volume":"623","author":"AL Ling","year":"2023","unstructured":"Ling AL, Solomon IH, Landivar AM, et al. Clinical trial links oncolytic immunoactivation to survival in glioblastoma. Nature. 2023;623:157\u201366.","journal-title":"Nature"},{"key":"2408_CR61","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1002\/sim.3840","volume":"29","author":"LV Rubinstein","year":"2010","unstructured":"Rubinstein LV, Steinberg SM, Kummar S, et al. The statistics of phase 0 trials. Stat Med. 2010;29:1072\u20136.","journal-title":"Stat Med"},{"key":"2408_CR62","first-page":"567","volume":"19","author":"TT Batchelor","year":"2016","unstructured":"Batchelor TT, Gerstner ER, Ye X, et al. Feasibility, phase I, and phase II studies of tandutinib, an oral platelet-derived growth factor receptor-\u03b2 tyrosine kinase inhibitor, in patients with recurrent glioblastoma. Neuro Oncol. 2016;19:567\u201375.","journal-title":"Neuro Oncol"},{"key":"2408_CR63","doi-asserted-by":"publisher","first-page":"3820","DOI":"10.1158\/1078-0432.CCR-17-3348","volume":"24","author":"N Sanai","year":"2018","unstructured":"Sanai N, Li J, Boerner J, et al. Phase 0 trial of AZD1775 in First-Recurrence glioblastoma patients. Clin Cancer Res. 2018;24:3820\u20138.","journal-title":"Clin Cancer Res"},{"key":"2408_CR64","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3892\/mco.2020.2114","volume":"13","author":"J Quillin","year":"2020","unstructured":"Quillin J, Patel R, Herzberg E, et al. A phase 0 analysis of Ixazomib in patients with glioblastoma. Mol Clin Oncol. 2020;13:43.","journal-title":"Mol Clin Oncol"},{"key":"2408_CR65","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/s41591-022-02141-2","volume":"29","author":"IK Mellinghoff","year":"2023","unstructured":"Mellinghoff IK, Lu M, Wen PY, et al. Vorasidenib and Ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial. Nat Med. 2023;29:615\u201322.","journal-title":"Nat Med"},{"key":"2408_CR66","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1056\/NEJMoa2304194","volume":"389","author":"IK Mellinghoff","year":"2023","unstructured":"Mellinghoff IK, van den Bent MJ, Blumenthal DT, et al. Vorasidenib in IDH1- or IDH2-Mutant Low-Grade glioma. N Engl J Med. 2023;389:589\u2013601.","journal-title":"N Engl J Med"},{"key":"2408_CR67","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1200\/JCO.2006.06.6290","volume":"25","author":"J Weingart","year":"2007","unstructured":"Weingart J, Grossman SA, Carson KA, et al. Phase I trial of Polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial. J Clin Oncol. 2007;25:399\u2013404.","journal-title":"J Clin Oncol"},{"key":"2408_CR68","doi-asserted-by":"publisher","first-page":"7401","DOI":"10.1158\/1078-0432.CCR-07-0781","volume":"13","author":"JG Kuhn","year":"2007","unstructured":"Kuhn JG, Chang SM, Wen PY, et al. Pharmacokinetic and tumor distribution characteristics of Temsirolimus in patients with recurrent malignant glioma. Clin Cancer Res. 2007;13:7401\u20136.","journal-title":"Clin Cancer Res"},{"key":"2408_CR69","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s00280-011-1773-y","volume":"69","author":"DA Reardon","year":"2012","unstructured":"Reardon DA, Wen PY, Alfred Yung WK, et al. Ridaforolimus for patients with progressive or recurrent malignant glioma: a perisurgical, sequential, ascending-dose trial. Cancer Chemother Pharmacol. 2012;69:849\u201360.","journal-title":"Cancer Chemother Pharmacol"},{"key":"2408_CR70","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1158\/1078-0432.CCR-12-2481","volume":"19","author":"J Drappatz","year":"2013","unstructured":"Drappatz J, Brenner A, Wong ET, et al. Phase I study of GRN1005 in recurrent malignant glioma. Clin Cancer Res. 2013;19:1567\u201376.","journal-title":"Clin Cancer Res"},{"key":"2408_CR71","doi-asserted-by":"publisher","first-page":"4786","DOI":"10.1158\/1078-0432.CCR-16-0048","volume":"22","author":"R Xu","year":"2016","unstructured":"Xu R, Shimizu F, Hovinga K, et al. Molecular and clinical effects of Notch Inhibition in glioma patients: A phase 0\/I trial. Clin Cancer Res. 2016;22:4786\u201396.","journal-title":"Clin Cancer Res"},{"key":"2408_CR72","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1093\/neuonc\/noz164","volume":"22","author":"I Arrillaga-Romany","year":"2019","unstructured":"Arrillaga-Romany I, Odia Y, Prabhu VV, et al. Biological activity of weekly ONC201 in adult recurrent glioblastoma patients. Neuro Oncol. 2019;22:94\u2013102.","journal-title":"Neuro Oncol"},{"key":"2408_CR73","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1093\/neuonc\/noac263","volume":"25","author":"V Moreno","year":"2023","unstructured":"Moreno V, Manuel Sep\u00falveda J, Reardon DA, et al. Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: A phase I, window-of-opportunity study. Neuro Oncol. 2023;25:1113\u201322.","journal-title":"Neuro Oncol"},{"key":"2408_CR74","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s12885-024-11846-1","volume":"24","author":"S Heuer","year":"2024","unstructured":"Heuer S, Burghaus I, Gose M, et al. PerSurge (NOA-30) phase II trial of perampanel treatment around surgery in patients with progressive glioblastoma. BMC Cancer. 2024;24:135.","journal-title":"BMC Cancer"},{"key":"2408_CR75","doi-asserted-by":"publisher","first-page":"6707","DOI":"10.1038\/s41467-024-50558-9","volume":"15","author":"HU Balinda","year":"2024","unstructured":"Balinda HU, Kelly WJ, Kaklamani VG, et al. Sacituzumab Govitecan in patients with breast cancer brain metastases and recurrent glioblastoma: a phase 0 window-of-opportunity trial. Nat Commun. 2024;15:6707.","journal-title":"Nat Commun"},{"key":"2408_CR76","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1158\/1078-0432.CCR-24-2311","volume":"31","author":"EQ Lee","year":"2025","unstructured":"Lee EQ, Alexander BM, Romo CG, et al. Phase I study of Adavosertib with radiotherapy and Temozolomide in newly diagnosed glioblastoma and intratumoral drug levels in recurrent glioblastoma. Clin Cancer Res. 2025;31:983\u201392.","journal-title":"Clin Cancer Res"},{"key":"2408_CR77","doi-asserted-by":"publisher","first-page":"eadn6274","DOI":"10.1126\/scitranslmed.adn6274","volume":"17","author":"V Rendo","year":"2025","unstructured":"Rendo V, Lee EQ, Bossi C, et al. A window-of-opportunity trial reveals mechanisms of response and resistance to Navtemadlin in patients with recurrent glioblastoma. Sci Transl Med. 2025;17:eadn6274.","journal-title":"Sci Transl Med"},{"key":"2408_CR78","doi-asserted-by":"crossref","unstructured":"Ramos-Fresnedo A, Al-Kharboosh R, Twohy EL et al. Phase 1, dose escalation, nonrandomized, Open-Label, clinical trial evaluating the safety and preliminary efficacy of allogenic Adipose-Derived mesenchymal stem cells for recurrent glioblastoma: A clinical trial protocol. Neurosurg Pract 2023;4.","DOI":"10.1227\/neuprac.0000000000000062"},{"key":"2408_CR79","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1080\/14796694.2024.2383064","volume":"20","author":"SA Cain","year":"2024","unstructured":"Cain SA, Topp M, Rosenthal M, et al. A perioperative study of Safusidenib in patients with IDH1-mutated glioma. Future Oncol. 2024;20:2533\u201345.","journal-title":"Future Oncol"},{"key":"2408_CR80","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/s41586-019-1564-x","volume":"573","author":"V Venkataramani","year":"2019","unstructured":"Venkataramani V, Tanev DI, Strahle C, et al. Glutamatergic synaptic input to glioma cells drives brain tumour progression. Nature. 2019;573:532\u20138.","journal-title":"Nature"},{"key":"2408_CR81","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/s41586-019-1563-y","volume":"573","author":"HS Venkatesh","year":"2019","unstructured":"Venkatesh HS, Morishita W, Geraghty AC, et al. Electrical and synaptic integration of glioma into neural circuits. Nature. 2019;573:539\u201345.","journal-title":"Nature"},{"key":"2408_CR82","doi-asserted-by":"crossref","unstructured":"Chen E, Ling AL, Reardon DA, Chiocca EA. Lessons learned from phase 3 trials of immunotherapy for glioblastoma: time for longitudinal sampling? Neuro Oncol; 2023.","DOI":"10.1093\/neuonc\/noad211"},{"key":"2408_CR83","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1093\/jnci\/djp079","volume":"101","author":"C Le Tourneau","year":"2009","unstructured":"Le Tourneau C, Lee JJ, Siu LL. Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst. 2009;101:708\u201320.","journal-title":"J Natl Cancer Inst"},{"key":"2408_CR84","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0167-9473(98)00095-4","volume":"30","author":"E Reiner","year":"1999","unstructured":"Reiner E, Paoletti X, O\u2019Quigley J. Operating characteristics of the standard phase I clinical trial design. Comput Stat Data Anal. 1999;30:303\u201315.","journal-title":"Comput Stat Data Anal"},{"key":"2408_CR85","doi-asserted-by":"publisher","first-page":"4291","DOI":"10.1158\/1078-0432.CCR-16-0592","volume":"22","author":"Y Yuan","year":"2016","unstructured":"Yuan Y, Hess KR, Hilsenbeck SG, Gilbert MR. Bayesian optimal interval design: A simple and Well-Performing design for phase I oncology trials. Clin Cancer Res. 2016;22:4291\u2013301.","journal-title":"Clin Cancer Res"},{"key":"2408_CR86","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1038\/s41591-023-02347-y","volume":"29","author":"F Nassiri","year":"2023","unstructured":"Nassiri F, Patil V, Yefet LS, et al. Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1\/2 trial. Nat Med. 2023;29:1370\u20138.","journal-title":"Nat Med"},{"key":"2408_CR87","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1056\/NEJMoa2202028","volume":"386","author":"J G\u00e1llego P\u00e9rez-Larraya","year":"2022","unstructured":"G\u00e1llego P\u00e9rez-Larraya J, Garcia-Moure M, Labiano S, et al. Oncolytic DNX-2401 virus for pediatric diffuse intrinsic Pontine glioma. N Engl J Med. 2022;386:2471\u201381.","journal-title":"N Engl J Med"},{"key":"2408_CR88","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1056\/NEJMra2214183","volume":"390","author":"K-H Yu","year":"2024","unstructured":"Yu K-H, Healey E, Leong T-Y, Kohane IS, Manrai AK. Medical artificial intelligence and human values. N Engl J Med. 2024;390:1895\u2013904.","journal-title":"N Engl J Med"},{"key":"2408_CR89","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s12967-024-06013-w","volume":"23","author":"AF Abbasi","year":"2025","unstructured":"Abbasi AF, Asim MN, Dengel A. Transitioning from wet lab to artificial intelligence: a systematic review of AI predictors in CRISPR. J Transl Med. 2025;23:153.","journal-title":"J Transl Med"},{"key":"2408_CR90","doi-asserted-by":"publisher","first-page":"e262","DOI":"10.1016\/S1470-2045(19)30149-4","volume":"20","author":"KY Ngiam","year":"2019","unstructured":"Ngiam KY, Khor IW. Big data and machine learning algorithms for health-care delivery. Lancet Oncol. 2019;20:e262\u201373.","journal-title":"Lancet Oncol"},{"key":"2408_CR91","first-page":"44","volume":"8","author":"WT Wu","year":"2021","unstructured":"Wu WT, Li YJ, Feng AZ, et al. Data mining in clinical big data: the frequently used databases, steps, and methodological models. Mil Med Res. 2021;8:44.","journal-title":"Mil Med Res"},{"key":"2408_CR92","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1126\/science.1247005","volume":"343","author":"O Shalem","year":"2014","unstructured":"Shalem O, Sanjana NE, Hartenian E, et al. Genome-Scale CRISPR-Cas9 knockout screening in human cells. Science. 2014;343:84\u20137.","journal-title":"Science"},{"key":"2408_CR93","doi-asserted-by":"publisher","first-page":"eadc9020","DOI":"10.1126\/science.adc9020","volume":"378","author":"F Endo","year":"2022","unstructured":"Endo F, Kasai A, Soto JS, et al. Molecular basis of astrocyte diversity and morphology across the CNS in health and disease. Science. 2022;378:eadc9020.","journal-title":"Science"},{"key":"2408_CR94","doi-asserted-by":"publisher","first-page":"eaba7365","DOI":"10.1126\/science.aba7365","volume":"367","author":"EA Stadtmauer","year":"2020","unstructured":"Stadtmauer EA, Fraietta JA, Davis MM, et al. CRISPR-engineered T cells in patients with refractory cancer. Science. 2020;367:eaba7365.","journal-title":"Science"},{"key":"2408_CR95","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1038\/s41591-020-1012-3","volume":"26","author":"T Strain","year":"2020","unstructured":"Strain T, Wijndaele K, Dempsey PC, et al. Wearable-device-measured physical activity and future health risk. Nat Med. 2020;26:1385\u201391.","journal-title":"Nat Med"},{"key":"2408_CR96","doi-asserted-by":"publisher","first-page":"121435","DOI":"10.1016\/j.biomaterials.2022.121435","volume":"283","author":"A Kar","year":"2022","unstructured":"Kar A, Ahamad N, Dewani M, Awasthi L, Patil R, Banerjee R. Wearable and implantable devices for drug delivery: applications and challenges. Biomaterials. 2022;283:121435.","journal-title":"Biomaterials"},{"key":"2408_CR97","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1023\/B:NEON.0000041878.93045.f5","volume":"69","author":"FF Lang","year":"2004","unstructured":"Lang FF, Asher A. Prospective clinical trials of brain tumor therapy: the critical role of neurosurgeons. J Neurooncol. 2004;69:151\u201367.","journal-title":"J Neurooncol"},{"key":"2408_CR98","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.nec.2018.08.013","volume":"30","author":"N Sanai","year":"2019","unstructured":"Sanai N. How to build a neurosurgical oncology practice specializing in gliomas. Neurosurg Clin N Am. 2019;30:129\u201336.","journal-title":"Neurosurg Clin N Am"}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-025-02408-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-025-02408-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-025-02408-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T14:03:44Z","timestamp":1758809024000},"score":1,"resource":{"primary":{"URL":"https:\/\/biosignaling.biomedcentral.com\/articles\/10.1186\/s12964-025-02408-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":98,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2408"],"URL":"https:\/\/doi.org\/10.1186\/s12964-025-02408-4","relation":{},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,25]]},"assertion":[{"value":"1 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"399"}}